On September 4, 2026, Citigroup initiated coverage of Dianthus Therapeutics (NASDAQCM:DNTH) with a Buy recommendation. The stock closed at $108.10, up from $107.85 the previous day, reflecting a weekly increase of 2.14%. Over the past month, however, the stock saw a slight decline of 2.08% from a close of $110.40.
As of August 28, 2026, analyst sentiment for Dianthus faced a positive consensus target mean of $142.14, an increase from $130.25 earlier in the month, suggesting a potential upside of 31.49%. The current recommendations include 10 strong buy, 11 buy, and 1 hold, totaling 95.5% positive recommendations.
Dianthus Therapeutics recently reported earnings on August 4, 2026, with an actual EPS of -0.90 against an estimated EPS of -0.87 and actual revenue of $761 billion compared to estimated revenue of $263.75 billion.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
